"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approved enzalutamide (Xtandi) for patients with metastatic castration-sensitive prostate cancer

FDA Approved enzalutamide (Xtandi) for patients with metastatic castration-sensitive prostate cancer

17 Dec 2019 8:19 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved enzalutamide (Xtandi; Astellas) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software